 CAMBRIDGE, Mass., Feb. 11, 2021 GLOBE NEWSWIRE -- Codiak BioSciences, Inc. Nasdaq: CDAK Codiak, a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, announced today the pricing of its underwritten public offering of 2,750,000 shares of its common stock at a public offering price of 21.00 per share, for gross proceeds of approximately 57.8 million, before deducting underwriting discounts and commissions and offering expenses. All of the shares are being offered by Codiak. In addition, Codiak has granted the underwriters a 30-day option to purchase up to an additional 412,500 shares of its common stock, at the public offering price, less underwriting discounts and commissions. All the shares to be sold in the proposed offering will be sold by Codiak. 